MX2014014682A - Glicoproteina 120 (gp120) estabilizada. - Google Patents

Glicoproteina 120 (gp120) estabilizada.

Info

Publication number
MX2014014682A
MX2014014682A MX2014014682A MX2014014682A MX2014014682A MX 2014014682 A MX2014014682 A MX 2014014682A MX 2014014682 A MX2014014682 A MX 2014014682A MX 2014014682 A MX2014014682 A MX 2014014682A MX 2014014682 A MX2014014682 A MX 2014014682A
Authority
MX
Mexico
Prior art keywords
hiv
provides
stabilized
polypeptidestabilized
polypeptideor
Prior art date
Application number
MX2014014682A
Other languages
English (en)
Spanish (es)
Inventor
Antu Dey
Andrea Carfi
Aemro Kassa
Indresh Srivastava
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014014682A publication Critical patent/MX2014014682A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014014682A 2012-06-18 2013-06-17 Glicoproteina 120 (gp120) estabilizada. MX2014014682A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661050P 2012-06-18 2012-06-18
PCT/EP2013/062553 WO2013189901A1 (en) 2012-06-18 2013-06-17 Stabilized gp120

Publications (1)

Publication Number Publication Date
MX2014014682A true MX2014014682A (es) 2015-03-04

Family

ID=48628698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014682A MX2014014682A (es) 2012-06-18 2013-06-17 Glicoproteina 120 (gp120) estabilizada.

Country Status (14)

Country Link
US (1) US20150183835A1 (enExample)
EP (1) EP2861249A1 (enExample)
JP (1) JP2015521592A (enExample)
KR (1) KR20150023735A (enExample)
CN (1) CN104619338A (enExample)
AU (1) AU2013279456A1 (enExample)
CA (1) CA2876762A1 (enExample)
IL (1) IL235898A0 (enExample)
IN (1) IN2014KN02740A (enExample)
MX (1) MX2014014682A (enExample)
RU (1) RU2015101081A (enExample)
SG (1) SG11201407995RA (enExample)
WO (1) WO2013189901A1 (enExample)
ZA (1) ZA201408840B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
RU2745373C2 (ru) * 2014-09-23 2021-03-24 БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. Рекомбинантные вакцины от fmdv и их применение
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10808011B2 (en) 2016-03-09 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant HIV-1 envelope proteins and their use
WO2018075989A1 (en) 2016-10-21 2018-04-26 Altor Bioscience Corporation Multimeric il-15-based molecules
US11136356B2 (en) 2017-10-16 2021-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
CN109851664A (zh) * 2017-11-30 2019-06-07 清华大学 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用
EP3810755A4 (en) 2018-06-19 2021-12-01 Nantcell, Inc. COMPOSITIONS AND METHODS OF TREATMENT FOR HIV
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786488B1 (fr) * 1998-11-27 2003-04-25 Orstom Mutants de la gp120 et leurs applications biologiques
EP1198468A4 (en) * 1999-06-25 2003-07-30 Progenics Pharm Inc STABILIZED VIRAL ENVELOPE PROTEINS AND THEIR USE
BRPI0815743A2 (pt) * 2007-08-24 2015-02-18 Novartis Ag Proteínas hiv env com modificações no laço v3
CA2774636C (en) * 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use

Also Published As

Publication number Publication date
RU2015101081A (ru) 2016-08-10
IL235898A0 (en) 2015-01-29
WO2013189901A1 (en) 2013-12-27
ZA201408840B (en) 2016-08-31
CN104619338A (zh) 2015-05-13
KR20150023735A (ko) 2015-03-05
JP2015521592A (ja) 2015-07-30
US20150183835A1 (en) 2015-07-02
AU2013279456A1 (en) 2014-12-18
SG11201407995RA (en) 2015-01-29
IN2014KN02740A (enExample) 2015-05-08
EP2861249A1 (en) 2015-04-22
CA2876762A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
MX2014014682A (es) Glicoproteina 120 (gp120) estabilizada.
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
WO2013085550A3 (en) V1v2 immunogens
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201290956A1 (ru) Вакцина против вич
WO2013016468A3 (en) Compositions and methods for improving potency and breadth or hiv antibodies
PH12015501156A1 (en) Pharmaceutical compositions
PH12013502442A1 (en) Inactivated dengue virus vaccine
IN2015DN03202A (enExample)
WO2011106100A3 (en) Method of inducing the production of protective anti-hiv-1 antibodies
WO2012047267A3 (en) Polyvalent immunogen
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
IN2014CH00395A (enExample)
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
ZA201307069B (en) Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
WO2015086738A3 (en) Hiv vaccine
IN2014DN09445A (enExample)
WO2012139097A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
AU2013235442A8 (en) Stable peptide mimetics of the HIV-1 gp41 pre-hairpin intermediate
WO2014210082A3 (en) Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
MX385188B (es) Vacuna de rinitis equina.
WO2012071521A3 (en) Adjuvant
WO2011139385A3 (en) Genetic signatures in hiv-1 subtype c envelope glycoproteins
WO2012109314A3 (en) Potent hiv inhibitors targeting ccr5 and gp41